Skip to main content

Nexlizet (bempedoic acid and ezetimibe)

Australian Prescription Medicine Decision Summary

Nexlizet was approved for the treatment of adults with hypercholesterolaemia, mixed dyslipidaemia and cardiovascular disease. Nexlizet is a fixed-dose combination medicine containing bempedoic acid and ezetimibe.
 

Published
Product name
Nexlizet
Active ingredient
Bempedoic acid and ezetimibe
Submission type
New combination medicine - Type B application
Decision
Approved for registration in the Australian Register of Therapeutic Goods (ARTG)
Decision date
Registration date
What this medicine was approved for

Hypercholesterolaemia and mixed dyslipidaemia

Nexlizet was approved to treat adults with primary hypercholesterolaemia or mixed dyslipidaemia. 

Primary hypercholesterolaemia means having a high level of cholesterol in the blood. It may be inherited from one parent (called ‘heterozygous familial’) or may not be inherited (called ‘non-familial’). 

Mixed dyslipidaemia means having unhealthy levels of different fats in the blood, such as cholesterol and triglycerides. 

Together with lifestyle changes, Nexlizet was approved to be taken:

  • with a statin when the highest dose the patient can tolerate, together with ezetimibe, has not lowered low-density lipoprotein cholesterol (LDL-C) enough. 
  • without a statin when the patient cannot tolerate a statin or should not take one for other medical reasons, and ezetimibe alone has not lowered LDL-C enough.
  • instead of separate bempedoic acid and ezetimibe tablets, with or without a statin.

Cardiovascular disease

Nexlizet was approved to treat adults who have atherosclerotic cardiovascular disease, or who are at high risk of developing it. 

Alongside measures to manage other risk factors, Nexlizet was approved to be taken:

  • when the highest statin dose the patient can tolerate, together with ezetimibe, has not provided enough control of LDL-C levels.
  • when the patient cannot tolerate a statin, or should not take one for other medical reasons, and ezetimibe has not provided enough control of LDL-C levels instead of separate bempedoic acid and ezetimibe tablets.
How this medicine works

Bempedoic acid and ezetimibe lower LDL-C in different ways.

Bempedoic acid becomes active in the liver where it blocks an enzyme that makes cholesterol. 

Ezetimibe blocks a protein called Niemann-Pick C1-Like 1 (NPC1L1), which is present in the small intestine and helps cholesterol absorption. By blocking NPC1L1, less cholesterol is absorbed in the small intestine, so less cholesterol reaches the liver. 

Both medicines result in lower levels of cholesterol in the liver, which causes the liver to produce more LDL receptors. These receptors remove LDL particles from the blood, which lowers LDL-C levels. 

High LDL-C levels can contribute to the development of atherosclerotic cardiovascular disease. LDL-C can cause fatty deposits, known as plaques, to build up in artery walls. These plaques can gradually narrow or block the arteries, reducing blood flow and increasing the risk of a heart attack or stroke.

A plaque may also break open and trigger a blood clot. A clot that blocks blood flow to the heart can cause a heart attack, while one that blocks blood flow to the brain can cause a stroke.

Bempedoic acid also reduces the production of fatty acids in the liver which may help reduce the amount of harmful fats circulating in the blood. This may also help prevent plaque formation.

By lowering the levels of LDL-C, and other lipids in the blood, Nexlizet reduces cardiovascular risk.

Why the TGA approved or did not approve this medicine

The safety and effectiveness of Nexlizet was assessed in one main trial of 301 patients that received either Nexlizet, bempedoic acid alone, ezetimibe alone or placebo (an inactive treatment used for comparison). Patients continued taking the highest statin dose they could tolerate. 

After 12 weeks, Nexlizet lowered LDL-C more than bempedoic acid alone, ezetimibe alone or placebo. These results show that combining bempedoic acid and ezetimibe provides an additional LDL-C-lowering effect compared with either medicine used alone.

Nexlizet was not assessed in a dedicated cardiovascular outcomes trial (which measures events such as heart attack, stroke or death from cardiovascular disease). However, a separate trial of bempedoic acid included a group of patients who were also taking ezetimibe. This trial showed a trend for improved cardiovascular outcomes in the group taking bempedoic acid and ezetimibe.  

The use of Nexlizet to improve cardiovascular outcomes is supported by broader evidence showing improved outcomes when bempedoic acid and ezetimibe are taken separately and by their ability to lower LDL-C when either are used together or separately.

Evidence supporting the safety of Nexlizet comes mainly from the key trial of the combined medicine. This evidence is supported by other clinical studies that included groups of patients receiving both bempedoic acid and ezetimibe. Extensive safety information for each medicine used separately was also submitted. 

Overall, the safety of Nexlizet was similar to the known safety of its two ingredients. The analysis of safety data did not uncover new safety concerns that had not already been identified for either medicine.

The TGA decided that the application provided sufficient evidence supporting the safety and effectiveness of Nexlizet and the medicine can be registered in Australia. 

More detailed information on why the TGA approved Nexlizet will be published in the upcoming Australian Public Assessment Report (AusPAR).

For comprehensive information on potential side effects and risks, refer to the Consumer Medicine Information (CMI) leaflet or Product Information (PI) document.  

This decision summary will not be updated to reflect any subsequent changes and may therefore not contain the most current information about the medicine. For the latest information, refer to the medicine’s CMI or PI.

Consumer Medicine Information (CMI)

The CMI leaflet offers guidance for consumers to support safe and effective use of the medicine. The CMI includes information on dose, how to use the medicine properly, potential side effects, safety precautions, storage instructions and more. 

Australian CMIs can be accessed through the searchable TGA eBusiness Services or ARTG databases.

Product Information (PI)

The PI document provides essential prescribing information for health professionals, including details on dosage recommendations, pregnancy category, contraindications, precautions and potential side effects.

Australian PIs can be accessed through the searchable TGA eBusiness Services or ARTG databases.

Sponsor
Other resources

For health advice and information, including a symptom checker and service finder refer to the healthdirect website.

For information on medicines subsidised by the Australian Government refer to the Pharmaceutical Benefits Scheme (PBS) website.

For data and reports on health and welfare topics in Australia refer to the Australian Institute of Health and Welfare website.